There are not many people who may know about Tonghua Dongbao, but many foreign companies like Novo Nordisk, Lilly, and Sanofi may not be familiar with many people.
As early as more than a decade ago, the recombinant human insulin, founded by Dr. Gan Zhongru, was established in Beijing and Jilin Tonghua, respectively. As a pillar industry of Dongbao Industrial Group, the self-developed recombinant human insulin, “Gan Shulin”, was filled in 1998. The domestic gap has made China, after the United States and Denmark, the third country in the world to produce recombinant human insulin, breaking the pattern that Chinese diabetic patients have relied on imports for human insulin products. However, it is still rare to see the sale of human insulin products produced by Tonghua Dongbao or Beijing Ganli Pharmaceuticals in hospitals or pharmacies in China.
How can domestic insulin be difficult to break through the foreign product? Where did the human insulin products with independent intellectual property rights produced by Chinese pharmaceutical companies go?
According to the survey, the selling price of foreign assets of insulin pens sold in China's market is much higher than that of other Asian countries, and even more expensive than developed countries in Europe and America. The retail price of insulin pens (3.0ml or 300 units each) in the Chinese market is generally 288~300 yuan, while the retail price of the same specification of insulin pens in other countries is 15~ in the US market. $17 (with a discount of more than 5); each in the EU market is priced at around 12 euros. That is to say, in the European and American countries, the retail price of each 3.0ml insulin pen is converted into RMB 106-120, which is much lower than the price in the Chinese market. In Asia, the price of India is equivalent to RMB 80-90 per unit; the price in Pakistan is similar to that in India; in the Southeast Asian countries such as Malaysia, Singapore and Thailand, where the economy is relatively developed, the 3.0ml insulin injection pen The price is only 120~150 yuan; the price of Egypt is converted into RMB 85~120 yuan. It seems that China has become one of the most expensive countries for insulin injection pens worldwide. The per capita national income of our country is reported to be ranked more than 100 in the world.
In fact, Tonghua Dongbao has already developed and launched a new product of insulin injection pen with its own brand, Gan Shulin, a few years ago. The market retail price is 59.9 yuan, and its new Dongbao automatic insulin injection pen The branch is only 196 yuan. In contrast, the similar products produced by Novo Nordisk are priced at about 288-360 yuan each. But what is strange is that in the hospitals or pharmacies in East China, the sales of low-cost insulin pens of Tonghua Dongbao are basically not seen.
After the investigation, it was found that foreign investors succeeded in blocking domestic insulin outside the market by virtue of its strong economic strength and marketing network throughout the country, together with the interest chain formed by hospitals and pharmaceutical distribution companies. Domestically-recombinant human insulin can only go the old way that most domestic pharmaceutical companies are still taking away - exporting insulin raw materials to foreign countries, and then processing them into domestically produced preparations.
Although the penetration rate of insulin pens is low, foreign companies are not worried about the sales of their products in the Chinese market. There are currently 50 million diabetic patients in China, and some patients must purchase at their own expense due to their medical needs. According to reports, Novo Nordisk, Eli Lilly and Sanofi-Antewan have plans to expand insulin pen production in China, while China's domestic insulin pen manufacturers have been struggling to date, and their insulin APIs are mostly emptied. Some insulin APIs can only be exported to overseas markets.
The recombinant human insulin injection pen has been monopolized by foreign companies for more than 20 years, and it directly hurts the interests of the majority of diabetic patients (most of them belong to the middle and low income groups). They are eager to buy low-priced products, and hope that the relevant departments can take the law in India, Pakistan and In developing countries such as Egypt, the maximum price of such products should be established as soon as possible, so that cheap domestic and international insulin pens can benefit low- and middle-income patients.